SCHEMBL1406485

SCHEMBL1406485

COc1cc(C)c2cc(C(=O)N(N)C(=O)c3ccccc3)c(=O)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.47
ALDH1A1 P00352 8/20 0.47
NPC1 O15118 3/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 2/20 0.47
KMT2A Q03164 5/20 0.42
MAPT P10636 3/20 0.42
GAA P10253 3/20 0.42
GLA P06280 2/20 0.42
NPBWR1 P48145 1/20 0.42
SLC16A3 O15427 1/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AR P10275 1/20 0.40
DRD4 P21917 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5086400 0.89 MEN1 (0.42) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL1406630 0.82 ALDH1A1 (0.71) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL1406487 0.80 NPC1 (0.56) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL1406253 0.78 SLC16A3 (0.59) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL29968097 0.72 ALDH1A1 (0.66) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL52178 0.72 ALDH1A1 (0.66) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL14326164 0.72 MAOB (0.65) KDM4EALDH1A1KMT2AMAPTGAA
SCHEMBL1406862 0.72 MAOA (0.49) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL13996204 0.70 ALDH1A1 (0.56) KDM4EALDH1A1NPC1POLBRAB9A
SCHEMBL28183213 0.70 CES2 (0.65) KDM4EALDH1A1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 EP disclosed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 WO disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR KDM4E 2436/4885ALDH1A1 1795/4885NPC1 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.